CARLSBAD, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will present at the following upcoming investor conferences:
- Oppenheimer 36th Annual Healthcare Life Sciences Conference on Wednesday, February 25, 2026, at 1:20 p.m. ET (virtual)
- Leerink Partners Global Healthcare Conference on Tuesday, March 10, 2026, at 2:20 p.m. ET in Miami, FL
Live webcasts of each presentation will be available here and in the investors section of the company’s website at www.designtx.com.The webcasts will be archived for at least 30 days following each presentation.
About Design Therapeutics
Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC® gene targeted chimera small molecules. The company’s GeneTAC® molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. In addition to its clinical-stage GeneTAC® programs, DT-216P2, in development for patients with Friedreich ataxia, and DT-168, for Fuchs endothelial corneal dystrophy, the company is advancing DT-818 for myotonic dystrophy type-1, and a program in Huntington’s disease. Discovery efforts are underway for multiple genomic medicines. For more information, please visit designtx.com.
Contact:
Renee Leck, THRUST
renee@thrustsc.com
